• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • Skip to footer

Biolocity

Emory and Georgia Tech

  • Home
  • Funding
    • Application
  • Lab2Launch
  • Approach
    • Program History
  • Team
    • Oversight Committee
  • Success Stories
    • Funded Projects
    • Testimonials
  • Recent News
  • DRIVe
  • Legal Office Hours
  • B2MTalks
  • Events
    • Resources
You are here: Home / News / $1.6M Raise for NephroDI Therapeutics

May 15, 2021 by Christina Wessels

$1.6M Raise for NephroDI Therapeutics

Biolocity graduate company, NephroDI Therapeutics, recently raised $1.6M to advance the development of a treatment for Nephrogenic Diabetes Insipidus (NDI), a pediatric kidney disease.  The team is collaborating with Xontogeny, a Boston based life sciences accelerator, to support their creation of therapies to treat children suffering from NDI.  Learn more about their collaboration here.

The NephroDI Team, Dr. Jeff Sands and Dr. Janet Klein, received support from the Biolocity program in 2018 and we are thrilled for their continued success and technology development.

“The Biolocity team provided invaluable assistance that moved our project from an NIH focus to a commercial venture. They recognized the value of our technology and how to promote it to industry. We would not have succeeded without their expertise.”

– Jeff M. Sands, MD, Renal Division Director, Emory University

Filed Under: News, Technology

Reader Interactions

Primary Sidebar

Footer

Connect with us

  • Email
  • Facebook
  • LinkedIn
  • Twitter

Keep In Touch

Register here to receive our emails on upcoming events and funding opportunities.

Copyright © 2023 · Executive Pro on Genesis Framework · WordPress · Log in